34th PAGE Meeting

Dubrovnik - Croatia
2-5 June, 2026

View abstracts

Home / 2026 – Dubrovnik – Croatia / Abstracts

← Back to filters

Abstracts (34)

I-092Elisa Calvier

Accelerating Gold Standard Evolution in Pharmacometrics: A Framework for Cross-Study Benchmarking of Covariate Modeling Methods

Wed, Jun 3, 2026 10:30AM–12:00PM

I-093Niklas Hartung

Mechanistic lumping of linear PBPK models

Wed, Jun 3, 2026 10:30AM–12:00PM

I-094Niklas Korsbo

Post-hoc model joining with Normalizing Flows for efficient and scalable multi-endpoint PKPD

Wed, Jun 3, 2026 10:30AM–12:00PM

I-095Peng Man

Apparent Time Dependence and Rethinking Random Effect under Single Time-to-Event Models

Wed, Jun 3, 2026 10:30AM–12:00PM

I-096Enrico Grisan

CVAE–LASSO: INTEGRATED L1-REGULARIZED COVARIATE SELECTION WITHIN A CONDITIONAL LATENT FRAMEWORK FOR POPULATION PHARMACOKINETIC MODELLING

Wed, Jun 3, 2026 10:30AM–12:00PM

I-097Mark Sale

QPC: Predicting Human Interpretation of VPC Plots

Wed, Jun 3, 2026 10:30AM–12:00PM

I-098Sabine Stübler

EVALUATION OF AUTOMATIC MODEL DEVELOPMENT TOOLS PYDARWIN AND PHARMPY USING CLINICAL POPULATION PK DATA

Wed, Jun 3, 2026 10:30AM–12:00PM

I-099Abraham Vaquero Castro

A Generative AI approach for reconstructing synthetic data cohorts for MBMA.

Wed, Jun 3, 2026 10:30AM–12:00PM

II-091Marcus Baaz

The Empirical Bayes Variational Autoencoder – A Neural ODE Approach for Population Modeling in Pharmacology

Wed, Jun 3, 2026 3:20PM–4:50PM

II-092Emmanuelle Comets

A novel workflow integrating PET microdosing data and therapeutic-dose pharmacokinetics across species to inform first-in-human dose selection

Wed, Jun 3, 2026 3:20PM–4:50PM

II-093Zhonghui Huang

A framework for nlmixr2auto: an open-source R package on CRAN for automated population pharmacokinetic modelling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-094Anna Largajolli

Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients

Wed, Jun 3, 2026 3:20PM–4:50PM

II-095Luca Marzano

IMPROVING CLINICAL DATA HARMONIZATION FOR POPULATION APPROACHES USING GRAPH DATABASES

Wed, Jun 3, 2026 3:20PM–4:50PM

II-096Matthias Pierre

COMPARISON OF MACHINE LEARNING ALGORITHMS FOR RAPID COMPARTMENTAL MDOEL SELECTION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-097Darian Schirr

Mechanistic PK/PD Modeling Framework for Targeted Covalent Inhibitors: Applications to Guide Lead Optimization, Inform Study Design, and Predict in vivo Efficacy

Wed, Jun 3, 2026 3:20PM–4:50PM

II-098Anitha Suram

A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL LINKING KIT SIGNALING TO MAST CELL DEGRANULATION AND DEPLETION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-099Gustaf Wellhagen

BOUNDED INTEGER MODELING OF NEUROPATHY, QUALITY OF LIFE AND ACUTE ADVERSE EVENT SCALES IN PATIENTS WITH COLORECTAL CANCER

Wed, Jun 3, 2026 3:20PM–4:50PM

III-091Massinissa Beldjenna

Modeling the stochasticity of bacterial resistance emergence to bacteriophages

Thu, Jun 4, 2026 9:50AM–11:20AM

III-092Jeroen Elassaiss-schaap

A population covariate modeling framework for IMPRES-M, the impulse-response modeling for population PK analysis based on P-splines

Thu, Jun 4, 2026 9:50AM–11:20AM

III-093E. Niclas Jonsson

A STRUCTURED APPROACH TO PHARMACOMETRIC COVARIATE MODELING: WHY THE ESTIMAND IS THE FIRST DECISION AND THE METHOD THE SECOND

Thu, Jun 4, 2026 9:50AM–11:20AM

III-094Mihaly Leiwolf

Model Ensembling and Machine Learning Approaches to Predict the First Dose of Amoxicillin in Intensive Care

Thu, Jun 4, 2026 9:50AM–11:20AM

III-095Ben Miles

A semi-mechanistic intranasal PBPK framework implemented in MoBi

Thu, Jun 4, 2026 9:50AM–11:20AM

III-096Antoine Pitoy

Generating Realistic Virtual Populations for In Silico Clinical Trials to Inform Phase 3 Trial Design: Application to Isatuximab in Relapsed Refractory Multiple Myeloma

Thu, Jun 4, 2026 9:50AM–11:20AM

III-097Johannes Schropp

Using Generative AI Variational Autoencoders with Neural Ordinary Differential Equations to Improve Nonlinear Mixed-Effects Pharmacometric Modeling

Thu, Jun 4, 2026 9:50AM–11:20AM

III-098Hidde van de Beek

Treating models as data: advancing model-based meta-analysis through aggregate data modelling

Thu, Jun 4, 2026 9:50AM–11:20AM

III-099Huixin Yu

BEYOND EMPIRICAL BIOAVAILABILITY SCALING: A MECHANISTIC MODEL INCORPORATING PRE- AND POST-SYSTEMIC SATURABLE PROCESSES TO CHARACTERIZE NON-LINEAR PK OF ORALLY ADMINISTERED SMALL MOLECULES

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-091Ilona Blanchard

Model Averaging for Individual Predictions in Joint Nonlinear Mixed-Effects Models

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-092

A NOVEL MATHEMATICAL FRAMEWORK TO PREDICT IN VIVO BISPECIFIC GTX-B001 BINDING IN SKIN AND TRANSLATION TO HUMANS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-093Anke E. Kip

AN ASYMPTOTIC THEORY ON THE COMPETITIVE BINDING OF THERAPEUTIC AND ENDOGENOUS ANTIBODIES TO FCRN

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-094Nefeli Maria Magaliou

THE TOP-DOWN PBFTPK MODELS VIS A VIS THE BOTTOM-UP PBPK MODELS IN EARLY DRUG DEVELOPMENT

Thu, Jun 4, 2026 13:40PM–15:10PM

IV-095Seongwon Park

QUANTITATIVE MAPPING OF FUNCTIONAL CYTOCHROME P450 ACTIVITIES IN ZEBRAFISH EMBRYOS: INTEGRATING PARENT-METABOLITE DATA VIA TOXICOKINETIC MODELING IN NAMS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-096Federico Reali

No One-Size-Fits-All: A Multi-Model Evaluation of Optimization-Based and Surrogate-Assisted Virtual Population Generation in QSP

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-097Erik Sjögren

Benchmarking a Mechanistic Immunogenicity Framework: Aligning Sequence-Based Epitope Predictions with Clinical Observations

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-098Stefan Van Den Berg

A Generic IgG Pharmacokinetic Model Applied to Adalimumab and Extended to Capture Anti-Drug Antibody effects

Thu, Jun 4, 2026 1:40PM–3:10PM